中国药理学通报2018，Vol.34Issue(2)：157-161,5.DOI:10.3969/j.issn.1001-1978.2018.02.003
靶向DNA损伤反应途径:PARP抑制剂抗肿瘤治疗研究进展
Targeting DNA damage response pathway: recent progress of PARP inhibitors in cancer therapy
郑宇静 1左彤彤 2封宇飞1
作者信息
- 1. 北京医院药学部,国家老年医学中心,北京100730
- 2. 上海交通大学医学院附属新华医院小儿神经外科,上海200092
- 折叠
摘要
Abstract
Genomic instability is one of the most pervasive characteristics of cancer cells,and DNA damage response (DDR) pathway plays a crucial role in genomic stability.The DDR pathway is a complex signaling network,which involves cell DNA repair,apoptosis and cell cycle regulation.Deficiencies in these repair pathways can result in several different genetic disorders,including cancer.Targeted therapy based on inhibiting the DDR pathway in cancers offers a novel therapy strategy for patients with tumors lacking specific DDR functions.Many small-mole-cule compounds targeting DDR pathway are typically developed for solid cancer therapy.The poly (ADP-ribose) polymerase (PARP) inhibitor is a kind of DDR inhibitors which exploits the principle of synthetic lethality to selectively kill cancer cells.This review highlights the molecular mechanisms of PARP inhibitor action,the progress of PARP inhibitors in cancer therapy,drug resistance and the challenge of PARP inhibitor in the future.关键词
DNA损伤反应通路/聚腺苷二磷酸核糖聚合酶抑制剂/协同致死/靶向治疗/乳腺癌易感基因/作用机制Key words
DNA damage response pathway/poly (ADP-ribose)polymerase (PARP) inhibitor/synthetic lethality/targeted therapy/breast cancer susceptibility gene/mechanism of action分类
医药卫生引用本文复制引用
郑宇静,左彤彤,封宇飞..靶向DNA损伤反应途径:PARP抑制剂抗肿瘤治疗研究进展[J].中国药理学通报,2018,34(2):157-161,5.
